Article
Hematology
Emmanuel Bachy, Roch Houot, Pierre Feugier, Krimo Bouabdallah, Reda Bouabdallah, Emmanuelle Nicolas Virelizier, Marie Maerevoet, Christophe Fruchart, Sylvia Snauwaert, Steven Le Gouill, Jean-Pierre Marolleau, Lysiane Molina, Cecile Molucon-Chabrot, Catherine Thieblemont, Herve Tilly, Fontanet Bijou, Corinne Haioun, Eric Van den Neste, Bettina Fabiani, Michel Meignan, Guillaume Cartron, Gilles Salles, Olivier Casasnovas, Franck Morschhauser
Summary: The combination of Obinutuzumab and lenalidomide has shown promising clinical efficacy and a manageable safety profile in various types of lymphoma. This study reported the efficacy and safety results for previously untreated patients with advanced follicular lymphoma. The combination treatment resulted in a high complete response rate, overall response rate, and favorable progression-free survival and overall survival. The most common adverse event was neutropenia.
Article
Hematology
Cedric Menard, Delphine Rossille, Joelle Dulong, Tien-Tuan Nguyen, Ilenia Papa, Maelle Latour, Nadege Bescher, Isabelle Bezier, Myriam Chouteau, Thierry Fest, Roch Houot, Franck Morschhauser, Karin Tarte
Summary: The study found that lenalidomide activated T cells in patients with FL, triggering gene changes related to effector memory T cell features, which were validated at the phenotypic and functional levels. Additionally, high effector T cell and regulatory T cell percentages had a negative clinical impact before and during treatment.
Review
Chemistry, Medicinal
Umut Yilmaz, Ayse Salihoglu, Teoman Soysal
Summary: Follicular lymphoma (FL) is a low-grade malignancy of B cells with variable clinical presentations, natural courses, and severity, requiring multiple lines of treatment. Chemoimmunotherapy is the standard care, but alternative treatments are limited for refractory or unfit patients. Lenalidomide combination with rituximab (LR) has shown promising results in clinical trials, offering superior efficacy to monotherapy options.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Oncology
Aino Rajamaki, Mika Hujo, Reijo Sund, Roosa E. I. Prusila, Milla E. L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Marc Sorigue, Juan-Manuel Sancho, Kaisa Sunela, Outi Kuittinen
Summary: This study examined the proportion of deaths from progressive lymphoma and the impact of follicular lymphoma (FL) on survival. The results showed that deaths from progressive lymphoma are nearly as common as deaths from other causes in FL patients during the rituximab era. Despite improvements in survival, there was evidence of excess mortality resulting from FL for at least 10 years after diagnosis.
Article
Oncology
Jordan B. Fenlon, Ryan J. Hutten, Skyler B. Johnson, Boyu Hu, Harsh Shah, Deborah M. Stephens, Amit Maity, David K. Gaffney, Randa Tao
Summary: Despite treatment guideline recommendations, the utilization of radiotherapy for early-stage FL is low, with higher utilization of observation and chemoimmunotherapy.
LEUKEMIA & LYMPHOMA
(2023)
Article
Oncology
Gwladys Claustre, Coralie Boulanger, Frederic Maloisel, Nelly Etienne-Selloum, Luc-Matthieu Fornecker, Eric Durot, Florian Slimano, Veronique Graff
Summary: This study compared the efficacy and safety of R-CHOP and G-CHOP treatments for previously untreated FL, and assessed the economic impact of introducing G. The results showed no significant difference in PFS between the two treatment strategies, but the G-CHOP group had higher hematological toxicity and infusion-related reactions during induction treatment. The introduction of G treatment resulted in additional costs per patient. Further studies including quality of life data are recommended.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Shu Liu, He Huang, Rong-xin Chen, Zhao Wang, Yan-ping Guan, Chen Peng, Xiao-jie Fang, Zhuo-jia Chen, Shao-xing Guan, Xia Zhu, Quan-guang Ren, Yu-yi Yao, Hong-bing Huang, Min Huang, Xue-ding Wang, Tong-yu Lin
Summary: This study evaluated the rationality of administering rituximab in FL patients with different grades based on concentration-response relationship analyses, finding that the first cycle trough concentration of rituximab was a significant independent risk factor for achieving complete response. Patients with lower initial rituximab concentrations in the 1/2 grade had unsatisfactory complete response rates compared to those in the 3 grade, highlighting the importance of individualized therapy based on pharmacokinetic considerations.
ACTA PHARMACOLOGICA SINICA
(2021)
Article
Oncology
Pier Luigi Zinzani, Thomas Rodgers, Dario Marino, Maurizio Frezzato, Anna Maria Barbui, Claudia Castellino, Erika Meli, Nathan H. Fowler, Gilles Salles, Bruce Feinberg, Nuwan C. Kurukulasuriya, Sascha Tillmanns, Stephan Parche, Debarshi Dey, Gunter Fingerle-Rowson, Sumeet Ambarkhane, Mark Winderlich, Grzegorz S. Nowakowski
Summary: The study demonstrated the additional treatment effect achieved by combining tafasitamab with lenalidomide in patients with R/R DLBCL, showing higher overall response rate, complete response rate, and improved survival endpoints compared to lenalidomide monotherapy.
CLINICAL CANCER RESEARCH
(2021)
Review
Nanoscience & Nanotechnology
Zhongmin Li, Yilun Liu, Xuedong Fang, Zhenbo Shu
Summary: Molecular targeted therapy not only directly inhibits the proliferation and metastasis of tumor cells, but also activates the immune system through various mechanisms. However, limitations such as poor water solubility, insufficient accumulation at the tumor site, and nonspecific targeting of immune cells hinder their application. Innovative nanomaterials have been developed to overcome these obstacles and enhance the immunomodulatory effects of molecular targeted drugs.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Hematology
Remy Dulery, Sylvain Lamure, Marc Delord, Roberta Di Blasi, Adrien Chauchet, Thomas Hueso, Cedric Rossi, Bernard Drenou, Benedicte Deau Fischer, Carole Soussain, Pierre Feugier, Nicolas Noel, Sylvain Choquet, Serge Bologna, Bertrand Joly, Laure Philippe, Milena Kohn, Sandra Malak, Guillemette Fouquet, Etienne Daguindau, Yassine Taoufik, Karine Lacombe, Guillaume Cartron, Catherine Thieblemont, Caroline Besson
Summary: Age >= 70 years, relapsed/refractory lymphoma, and recent administration of anti-CD20 therapy are risk factors for prolonged length of in-hospital stay and death for lymphoma patients hospitalized for Covid-19.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Medicine, General & Internal
Martin Hutchings, Rogier Mous, Michael Roost Clausen, Peter Johnson, Kim M. Linton, Martine E. D. Chamuleau, David John Lewis, Anna Sureda Balari, David Cunningham, Roberto S. Oliveri, Brian Elliott, Dena DeMarco, Ada Azaryan, Christopher Chiu, Tommy Li, Kuo-mei Chen, Tahamtan Ahmadi, Pieternella J. Lugtenburg
Summary: This study aimed to evaluate the safety and recommended dose of a novel bispecific antibody epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results showed that the full dose of 48 mg was identified as the recommended phase 2 dose, and no maximum tolerated dose was reached during the treatment. Epcoritamab demonstrated good antitumor activity in some patients during the study.
Article
Oncology
Yong-Pyo Lee, Jung Yong Hong, Sang Eun Yoon, Junhun Cho, Joon-Ho Shim, Yeonghak Bang, Won Seog Kim, Seok Jin Kim
Summary: This study retrospectively analyzed the efficacy of lenalidomide plus rituximab in patients with relapsed or refractory DLBCL. The results showed that this combination therapy may be a salvage option, especially for cases with secondary CNS involvement, but additional agents may be needed to prolong the duration of response.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Franck Morschhauser, Nilanjan Ghosh, Izidore S. Lossos, M. Lia Palomba, Amitkumar Mehta, Olivier Casasnovas, Don Stevens, Sudhakar Katakam, Andrea Knapp, Tina Nielsen, Ron McCord, Gilles Salles
Summary: The triplet regimen obinutuzumab-atezolizumab-lenalidomide (G-atezo-len) showed effectiveness and tolerability in patients with relapsed/refractory follicular lymphoma (FL), with a 36-month progression-free survival rate of 68.4%. Adverse events were noted in all treated patients, with two fatal events reported, both unrelated to the study drug.
BLOOD CANCER JOURNAL
(2021)
Article
Oncology
Rami Abdulbaki, Parastou Tizro, Victor E. Nava, Maria Gomes da Silva, Joao L. Ascensao
Summary: Primary splenic follicular lymphoma (PSFL) is a rare malignancy characterized by splenomegaly or cytopenias. Diagnosis requires correlation of histopathology, immunophenotype, and molecular profiling. Currently, splenectomy remains the main treatment for stage I PSFL, as management of this incurable disease continues to evolve.
Article
Biochemistry & Molecular Biology
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, Jose Antonio Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andres Jose Maria Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thieblemont
Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.